Elan once-daily nifedipine
Bayer's U.S. subsidiary, Miles Inc., will have exclusive U.S. marketing rights to Elan's sustained-release formulation of the calcium channel blocker under an agreement announced Oct. 17. Bayer was the discoverer of nifedipine and initially licensed U.S. rights to the product to Pfizer, which markets the drug as Procardia. Miles launched its own version of nifedipine as Adalat in 1986. Once approved, the Miles/Elan product will compete with Pfizer's recently launched once-a-day product Procardia XL. Elan filed an NDA in the U.S. for its once-a-day formulation on July 31.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.